Home › Alzheimer's Disease › NCT06547099
Study to Understand Novel Biomarkers in Researching Dementia
Blood Amyloid, Tau, and Neurodegeneration Biomarkers and Prediction of Clinical Onset, Cognitive Decline, and Dementia Diagnosis
Who can join
Ages 60 and older · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * At least 60 years of age * 80% of the newly enrolled clinic-based cohort will have symptoms of forgetfulness, mild cognitive impairment, mild dementia, or Alzheimer's disease as determined by their medical chart and/or provider * All SEABIRD participants will be invited to participate regardless of their cognitive status Exclusion Criteria: * Unable to perform one or more basic activities of daily living (eating, bathing, dressing, ambulating, toileting) due to cognitive impairment * Uncontrolled hepatitis B, hepatitis C, or HIV at time of blood collection * Taking a disease-modifying drug for AD at time of enrollment * Blood transfusion in the last three months * Unwilling or unable to participate in all study activities
About the study
The purpose of this study is to determine the relationships between amyloid, tau, and neurodegeneration biomarkers in the blood and the presence of Alzheimer's disease (AD) pathology, clinical cognitive decline, and diagnosis. We aim to understand how well blood-based biomarkers can diagnose and predict Alzheimer's disease, which will help to further develop and validate blood tests for the disease.
What is being tested
- Clinical tau PET (diagnostic test)
- Clinical amyloid test (diagnostic test)
- Research blood collection (other)
- Cognitive assessments (other)
Sponsor: Washington University School of Medicine · Participants: 1,800 · Started: Aug 14, 2024
Contact the study team
- Lisa Soke · Phone: 314-747-4857
Official record on ClinicalTrials.gov — NCT06547099
Locations in the U.S.
| Missouri | Washington University School of Medicine, St Louis |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.